Accepting PhD Students

1989 …2020
If you made any changes in Pure these will be visible here soon.

Personal profile


Professor Roger Phillips was appointed Professor of Cancer Pharmacology in July 2014.

Following a BSc in Marine Biology and Biochemistry (Joint Honours) from University College of North Wales, Bangor, Roger specialised in Cancer Pharmacology gaining his PhD in 1988 from the University of Bradford (under Profs John Double and Mike Bibby). After an initial postdoctoral position in Bradford, he moved to the School of Pharmacy, University of Southern California, Los Angeles to work with Dr Neil Gibson in 1991. He returned to Bradford in 1993 and secured academic appointments as lecturer (1996 to 2001), Senior Lecturer (2001 to 2003) and Reader (2003 to 1014) in Cancer Pharmacology. In July 2014, Roger was appointed as Professor of Cancer Pharmacology at the University of Huddersfield. He was also appointed as Director of Research in the School of Applied Sciences in August 2015.

His research focuses on the preclinical and early clinical evaluation of novel anti-cancer drugs with a specific interest in the tumour microenvironment as a target for drug development. His research has had clinical impact through the development of EO9 as a therapeutic drug for the treatment of superficial bladder cancer. He has published extensively in internationally recognised journals, has successfully supervised over 20 PhD students and continues to present his work at national and international conferences. He is a committee member of the European Organisation for the Research and Treatment of Cancer (EORTC) Drug Development Committee and the Pharmacology and Molecular Mechanism Group. He is also an editorial board member for the British Journal of Pharmacology. 

Research Expertise and Interests

  • Preclinical development of novel anti-cancer drugs
  • Phenotype based screening
  • Development of experimental models that reflect the complexity of tumour biology
  • The hypoxic tumour microenvironment as a target for drug development
  • Drug delivery to hypoxic regions of solid tumours

Research Degree Supervision

Click Here to see all postgraduate research opportunities with Professor Roger Philips

Research Expertise and Interests

  • Biochemistry
  • Molecular Medicine
  • Cancer Research
  • Drug Development
  • Biomarker Research
  • Pharmaceutics

Fingerprint Dive into the research topics where Roger Phillips is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
apaziquone Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Cells Chemical Compounds
Tumors Chemical Compounds
Ligands Chemical Compounds
Cytotoxicity Chemical Compounds
Pharmaceutical Preparations Medicine & Life Sciences
Ruthenium Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1989 2020

Synthesis, structural and in-vitro functional studies of half-sandwich platinum group metal complexes having various bonding modes of benzhydrazone derivative ligands

Shadap, L., Tyagi, J. L., Poluri, K. M., Pinder, E., Phillips, R., Kaminsky, W. & Kollipara, M. R., 15 Jan 2020, In : Polyhedron. 176, 10 p., 114293.

Research output: Contribution to journalArticle

Coordination Complexes
Metal complexes

Utilization of novel self-nanoemulsifying formulations (SNEFs) loaded paclitaxel for the treatment prosperity of bladder cancer

Abdallah, Q. M. A., Kazi, M., Khaleel, M. A., Al-Deeb, I., Nasr, A-R. T. & Phillips, R., 10 Jan 2020, In : Journal of Drug Delivery Science and Technology. 101514.

Research output: Contribution to journalArticle

Urinary Bladder Neoplasms
Surface-Active Agents

Anticancer, antifungal and antibacterial potential of bis(β-ketoiminato)ruthenium(II) carbonyl complexes

Madzivire, C. R., Caramés-Méndez, P., Pask, C. M., Phillips, R. M., Lord, R. M. & McGowan, P. C., 1 Dec 2019, In : Inorganica Chimica Acta. 498, 119025.

Research output: Contribution to journalArticle

cultured cells

Cellular uptake and efflux of palbociclib in vitro in single cell and spheroid models s

Jove, M., Spencer, J. A., Hubbard, M. E., Holden, E. C., O'dea, R. D., Brook, B. S., Phillips, R. M., Smye, S. W., Loadman, P. & Twelves, C. J., 1 Aug 2019, In : Journal of Pharmacology and Experimental Therapeutics. 370, 2, p. 242-251 10 p.

Research output: Contribution to journalArticle

Open Access
Pharmaceutical Preparations
MCF-7 Cells
Cyclin-Dependent Kinase 6
1 Citation (Scopus)

Discovery of selective, antimetastatic and anti-cancer stem cell metallohelices via post-assembly modification

Song, H., Rogers, N., Allison, S. J., Brabec, V., Bridgewater, H., Kostrhunova, H., Markova, L., Phillips, R., Pinder, E., Shepherd, S., Young, L., Zajac, J. & Scott, P., 7 Oct 2019, In : Chemical Science. 10, 37, p. 8547-8557 11 p.

Research output: Contribution to journalArticle

Open Access
Stem cells
Pharmaceutical Preparations
Self assembly
Adenosine Triphosphatases

Activities 2006 2019

  • 7 PhD Examination
  • 4 Invited talk
  • 1 Editorial work
  • 1 Membership of committee

PhD External Examiner at the Universit Putra Malaysia

Roger Phillips (Examiner)
19 Nov 2019

Activity: Examination typesPhD Examination

The preclinical and clinical development of Apaziquone - the trials and tribulations of working in drug development

Roger Phillips (Keynote speaker)
23 Oct 201925 Oct 2019

Activity: Talk or presentation typesInvited talk

PhD External Examination at the University of Leeds

Roger Phillips (Examiner)
14 Oct 2019

Activity: Examination typesPhD Examination

Targeting the hypoxic fraction of cancer

Roger Phillips (Speaker)
10 Oct 2019

Activity: Talk or presentation typesInvited talk


Targeted or Phenotypic Approaches to Cancer Drug Discovery

Roger Phillips (Speaker)
4 Oct 2019

Activity: Talk or presentation typesInvited talk